medigraphic.com
ISSN 1561-2937 (Print)

2017, Number 1

<< Back

Rev Cubana Cardiol Cir Cardiovasc 2017; 23 (1)

Secondary prevention in patients with surgical myocardial revascularization

Estévez ÁN, Chacón BEB, Rivas EE, de la Noval GR, Paredes CÁM, Rivero MNN

Language: Spanish
References: 42
Page:
PDF size: 342.74 Kb.


ABSTRACT

Cardiovascular disease, in particular, ischemic heart disease is a serious and growing problem in the world population. Patients undergoing Surgical Myocardial Revascularization are at very high risk for other lifethreatening episodes of illness. Secondary prevention is an important and cost-effective element of the cardiovascular disease control strategy. The control of risk factors and tools provided by Cardiac Rehabilitation programs emanates as the key terms of this review.


REFERENCES

  1. 1- Centro Nacional de Información de Ciencias Médicas Infomed. Al Día: Noticias de Salud. Aterosclerosis: Caso más antiguo de arteriosclerosis aparece en momia egipcia. Año 18 No.97 sábado 9 de abril de 2011

  2. 2- Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Riskfactors for long term coronary prognosis after initial myocardial infarction: the Framingham heart Study. Am J Epidemiol 1989; 130: 469-480.

  3. 3- LEWIS T. Diseases of the Heart. New York, Macmillan Publishing Co. Inc. 1933.

  4. 4- LEVINE SA. Some harmful effects of recumbency in treatment of heart disease. JAMA 1944; 126: 80-4.

  5. 5- Romero C. T. La rehabilitación cardíaca como punto de partida en la prevención secundaria de la enfermedad coronaria. Revista médica de Chile v.128 n.8 Santiago ago. 2000.

  6. 6- Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, Lopez-Jimenez F, McNallan SM, Patel M, Roger VL, Sellke FW, Sica DA, Zimmerman L; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015 Mar 10; 131(10):927-64.

  7. 7- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016; 37:2315-81.

  8. 8- Maroto JM, De Pablo C, Artigao R, Morales MD. Rehabilitación cardíaca. Análisis de coste-efectividad. Rev Esp Cardiol 1996; 49: 753-758

  9. 9- Piepoli MF, Corra U, Abreu A, Cupples M, Davos C, Doherty P, Ho fer S, Garcia-Porrero E, Rauch B, Vigorito C, Vo ller H, Schmid JP. Challenges in secondary prevention of cardiovascular diseases: a review of the current practice. Int J Cardiol. 2015;180:114-9.

  10. 10- Ian Graham Dan Atar, Knut Borch-Johnsen, Gudrun Boysen, Gunilla Burell, Renata Cifkova, Jean Dallongeville, et al. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Rev Esp Cardiol. 2008;61(1):e1-e49

  11. 11- Organización Mundial de la Salud. Dieta, nutrición y prevención de enfermedades crónicas.Informe de una consulta mixta de expertos OMS/FAO. Serie de Infor-mes Técnicos No. 916. Ginebra: OMS; 2004.

  12. 12- Smeeth L, Ebrahim S. Commentary: DINS, PINS and things - clinical and population perspectives on treatment effects. BMJ 2000; 321:952-953.

  13. 13- Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357(9261):995-1001.

  14. 14- ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1998; 28: 1328-1428

  15. 15- Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of Coronary Heart Disease in clinical practice. Eur Heart J 1998: 19: 1434-1503.

  16. 16- Sacks FM, Pteffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infartion in patients with average cholesterol levels.N Engl J Med 1996; 335: 1001-1009

  17. 17- Stone NJ, Robinson J, Lichtenstein LH, Bairey Merz CN, Blum CB, Eckel RH, et al.2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American Collegeof Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889-934.

  18. 18- Joint British Societies JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100 Suppl 2:ii1-67

  19. 19- Quiles J., Miralles-Vicedo B.: Estrategias de prevención secundaria del síndrome coronario agudo. Rev Esp Cardiol. - Vol. 67 Núm.10. 2014; 67:844-8.

  20. 20- Sacks FM, Pteffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infartion in patients with average cholesterol levels.N Engl J Med 1996; 335: 1001-1009.

  21. 21- Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. A meta-analysis of statin trials. J Am Coll Cardiol. 2014; 64:485-94.

  22. 22- Berusike JE, Levy RI, Kelsey SF, Passamany ER, Richardson JM, Loh IK et al. Effects of therapy with cholestyramine on progression of coronary arterioclerosis: results of the NH LB, type II Coronary Intervention Study. Circulation 1984; 69:313-324.

  23. 23- VelascoJA, CosínJ, MarotoJM, MuñizJ, Casasnovas JA, Plaza I, Abadal LT. Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca. Rev Esp Cardiol Vol. 53 Núm.08. 2000; 53:1095-120.

  24. 24- Pérez Coronel PL. Rehabilitación Cardíaca Integral. Prevención 1ria y 2ria de la Cardiopatía Isquémica. Cap 13. ECIMED, La Habana, Cuba; 2009; 109-122.

  25. 25- Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med. 2013; 159:758-69.

  26. 26- Diaz-Buschmann I, Castro A, Galve E, Calero MJ, Dalmau R, Guzmán G, et al. Comentarios a la guía de práctica clínica de la ESC sobre prevención de la enfermedad cardiovascular (versión 2012). Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. Rev Esp Cardiol. Vol. 65 Núm.10. 2012;65:869-73.

  27. 27- Eisenberg MJ, Windle SB, Roy N, OldW, Grondin F, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert CR, Madan M, Abramson B, Dehghani P. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation. 2016; 133:21-30.

  28. 28- Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;6:505-12

  29. 29- Pisinger C, Dossing M. A systematic review of health effects of electronic cigarettes. Prev Med. 2014; 69:248-60.MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence of 1994. Vasc Med Biol 1994; 4: 265-271

  30. 30- Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013; 382:1629-37.

  31. 31- Henningfield JE. Nicotine medications for smoking cessation. N Engl J. Med 1995;333:1196-203.

  32. 32- Sytkowski PA, D’Agostino RB, Berlanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697-703.

  33. 33- James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidencebased guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 5:507-20. 34- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;28:2159-219

  34. 35- MalmbergK, Efendic Randomized trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with AMI. 1995; 26: 57-65

  35. 36- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetics on the development and progress of the long term complications in insulin-dependent DM. N Engl J Med.1993;316:823-828

  36. 37- O’Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM. An overview of randomized trials of rehabilitation with exercice after myocardial infarction. Circulation 1989; 80: 234-244). (Velasco JA, Maureira JJ, editores. Rehabilitación del paciente cardíaco. Barcelona: Ed. Doyma, 1993.

  37. 38- WHO Working Group: A program for the physical rehabilitation of patients with acute myocardial infarction. Freigburg (March 4-6), 1968

  38. 39- Piepoli MF, Corrá U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010; 17(1):1-17.

  39. 40- De Backer G, Gohlke H, Graham I, Verschuren M, Albus C, Benlian P, et al. Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Cardiol. 2012; 65:937.e1-e66.

  40. 41- Borg GA. Psychophysical bases of perceived exertion. Med Sci Sport Exerc. 1982; 14(5):377-81.

  41. 42- Rivas Estany E. El ejercicio físico en la prevención y la rehabilitación cardiovascular. Rev Cubana Cardiol Cir Cardiovasc. 2011; 17(Supl 1):S23-9. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/download/189/129 43- Hernández García S, Mustelier Oquendo JA, Prendes lago E, Rivas Estany E. Fase de convalecencia en la rehabilitación cardiaca. Protocolo de actuación. Corsalud 2015 ene-mar; 7(1):60-75.

  42. 44- Rivas Estany E. Entrenamiento con ejercicios en rehabilitación cardíaca. En: García Porrero E, editor. Rehabilitación cardíaca. España: León (Sanofi); 2011




2020     |     www.medigraphic.com